Last $38.30 USD
Change Today -0.27 / -0.70%
Volume 500.8K
MYGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Peter D. Meldrum Ph.D.

Chief Executive Officer, President and Director, Myriad Genetics Inc.
AgeTotal Calculated CompensationThis person is connected to 67 board members in 6 different organizations across 9 different industries.

See Board Relationships
67$7,414,174
As of Fiscal Year 2013

Background*

Dr. Peter D. Meldrum, Ph.D., is a Co-founder of Myriad Genetics Inc. and has been its President and Chief Executive Officer since November 1991. Dr. Meldrum serves as the Secretary and Chairman of the Board of Directors of Golden Pine Ventures LLC. Dr. Meldrum was the founder of Pique Therapeutics Inc., Kylin Therapeutics Inc. and Rosetta Inpharmatics LLC. He has been involved in the founding of several biotechnology companies including : Pharmadigm Biosciences, Sonix ...

Read Full Background

Corporate Headquarters*

320 Wakara Way
Salt Lake City, Utah 84108

United States

Phone: 801-584-3600
Fax: 801-584-3640

Board Members Memberships*

Director
Director
Director and Member of Executive Committee
Former Director
Secretary and Chairman of the Board of Directors
1991-Present
Chief Executive Officer, President and Director
2012-Present
Director and Chairman of Compensation Committee

Education*

Honorary Doctorate 2009
The University of Utah
BS 1970
The University of Utah
MBA 1974
The University of Utah
ScD 2004
Westminster College

Other Affiliations*

Annual Compensation*

Salary$956,104
Bonus$812
Total Annual Compensation$956,916

Stock Options*

All Other Compensation$15,238
Exercised Options254,502
Exercised Options Value$5,769,583
Exercisable Options1,691,592
Exercisable Options Value$13,566,880
Unexercisable Options1,235,000
Unexercisable Options Value$4,924,020
Total Value of Options$24,260,482
Total Number of Options3,181,094

Total Compensation*

Total Annual Cash Compensation$2,213,654
Total Short Term Compensation$956,916
Other Long Term Compensation$15,238
Total Calculated Compensation$7,414,174
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $38.30 USD -0.27

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Joseph A. Chlapaty Chairman, Chief Executive Officer, President and Chairman of Executive Committee
Advanced Drainage Systems, Inc.
$454.2K
Peer M. Schatz Chairman of Management Board, Chief Executive Officer and Managing Director
Qiagen NV
$1.5M
Marc D. Grodman M.D.Founder, Chairman, Chief Executive Officer, President and Managing Director
Bio-Reference Laboratories Inc.
$1.2M
Russell Cummings Chief Executive Officer, Executive Director, and Member of Investment Committee
Imperial Innovations Group plc
210.0K GBP
Kimberly J. Popovits Chairman of the Board, Chief Executive Officer, President and Member of Non-Management Stock Option Committee
Genomic Health Inc.
$600.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.